Biomarkers in diabetic kidney disease

Therapy

Volumn 8, Issue 2, 2011, Pages 121-127

  Buddineni, Jaya P ^a   Chaudhary, Kunal ^a,b   Whaley Connell, Adam ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

ADMA; asymmetrical dimethylarginine; kidney injury molecule 1; KIM 1; MMP 9; neutrophil gelatinase associated lipocalcin; NGAL; TGF

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; GELATINASE B; HEMOGLOBIN A1C; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; MESSENGER RNA; N ACETYL BETA GLUCOSAMINIDASE; N(G),N(G) DIMETHYLARGININE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PODOCIN; TRANSFORMING GROWTH FACTOR BETA;

ALBUMINURIA; DIABETIC NEPHROPATHY; DISEASE COURSE; GENETIC SUSCEPTIBILITY; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY INJURY; MEDIATOR RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PEPTIDOMICS; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

EID: 79953237576     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.11.3     Document Type: Review

References (62)

1. Roglic G, Unwin N: Mortality attributable to diabetes: estimates for the year 2010. Diabetes Res. Clin. Pract. 87(1), 15-19 (2010).
2. Tuomilehto J, Lindstrom J, Eriksson JG et al.: Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344(18), 1343-1350 (2001).
3. Knowler WC, Barrett-Connor E, Fowler SE et al.: Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346(6), 393-403 (2002).
4. Lyssenko V, Jonsson A, Almgren P et al.: Clinical risk factors, DNA variants, and the development of Type 2 diabetes. N. Engl. J. Med. 359(21), 2220-2232 (2008).
5. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr: Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch. Intern. Med. 167(10), 1068-1074 (2007).
6. Lindstrom J, Tuomilehto J: The diabetes risk score: a practical tool to predict Type 2 diabetes risk. Diabetes Care 26(3), 725-731 (2003).
7. Adler S: Diabetic nephropathy: linking histology, cell biology, and genetics. Kidney Int. 66(5), 2095-2106 (2004).
8. Ruggenenti P, Remuzzi G: Time to abandon microalbuminuria? Kidney Int. 70(7), 1214-1222 (2006).
9. Birn H, Christensen EI: Renal albumin absorption in physiology and pathology. Kidney Int. 69(3), 440-449 (2006).
10. Toto RD: Microalbuminuria: definition, detection, and clinical significance. J. Clin. Hypertens. 6(11 Suppl. 3), 2-7 (2004).
11. Remuzzi G, Schieppati A, Ruggenenti P: Clinical practice. Nephropathy in patients with Type 2 diabetes. N. Engl. J. Med. 346(15), 1145-1151 (2002).
12. Hayden MR, Whaley-Connell A, Sowers JR: Renal redox stress and remodeling in metabolic syndrome, Type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am. J. Nephrol. 25(6), 553-569 (2005).
13. Paredi P, Biernacki W, Invernizzi G, Kharitonov SA, Barnes PJ: Exhaled carbon monoxide levels elevated in diabetes and correlated with glucose concentration in blood: a new test for monitoring the disease? Chest. 116(4), 1007-1011 (1999).
14. Wierusz-Wysocka B, Wysocki H, Byks H, Zozulinska D, Wykretowicz A, Kazmierczak M: Metabolic control quality and free radical activity in diabetic patients. Diabetes Res. Clin. Pract. 27(3), 193-197 (1995).
15. Hartnett ME, Stratton RD, Browne RW, Rosner BA, Lanham RJ, Armstrong D: Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care 23(2), 234-240 (2000).
16. Kneepkens CM, Ferreira C, Lepage G, RoyCC: The hydrocarbon breath test in the study of lipid peroxidation: principles and practice. Clin. Invest. Med. 15, 163-186 (1992).
17. Kneepkens CM, Lepage G, Roy CC: The potential of the hydrocarbon breath test as a measure of lipid peroxidation. Free Radic. Biol. Med. 17, 127-160 (1994).
18. Phillips M: Method for the collection and assay of volatile organic compounds in breath. Anal. Biochem. 247, 272-278 (1997).
19. Phillips M, Herrera J, Krishnan S, Zain M, Greenberg J, Cataneo RN: Variation in volatile organic compounds in the breath of normal humans. J. Chromatogr. B Biomed. Sci. Appl. 729, 75-88 (1999).
20. Phillips M, Cataneo RN, Cheema T, Greenberg J: Increased breath biomarkers of oxidative stress in diabetes mellitus. Clin. Chim. Acta. 344(1-2), 189-194 (2004).
21. Nishikawa T, Edelstein D, Du XL et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404(6779), 787-790 (2000).
22. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865), 813-820 (2001).
23. Hinokio Y, Suzuki S, Hirai M, Suzuki C, Suzuki M, Toyota T: Urinary excretion of 8-oxo-7, 8-dihydro-2′-deoxyguanosine as a predictor of the development of diabetic nephropathy. Diabetologia 45(6), 877-882 (2002).
24. Ong AC, Fine LG: Loss of glomerular function and tubulointerstitial fibrosis: cause or effect? Kidney Int. 45(2), 345-351 (1994).
25. Nath KA: Tubulointerstitial changes as a major determinant in the progression of renal damage. Am. J. Kidney Dis. 20(1), 1-17 (1992).
26. Eardley KS, Zehnder D, Quinkler M et al.: The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int. 69(7), 1189-1197 (2006).
27. Aros C, Remuzzi G: The renin-angiotensin system in progression, remission and regression of chronic nephropathies. J. Hypertens. Suppl. 20(3), S45-S53 (2002).
28. Zhang Y, Dall TM, Mann SE et al.: The economic costs of undiagnosed diabetes. Popul. Health Manag. 12(2), 95-101 (2009).
29. Derosa G, D'Angelo A, Tinelli C et al.: Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab. 33(2), 129-134 (2007).
30. Derosa G, Ferrari I, D'Angelo A et al.: Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 15(4), 219-224 (2008).
31. Glowinska-Olszewska B, Urban M: Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism 56(6), 799-805 (2007).
32. Thrailkill KM, Moreau CS, Cockrell GE et al.: Disease and gender-specific dysregulation of NGAL and MMP-9 in Type 1 diabetes mellitus. Endocrine 37(2), 336-343 (2010).
33. Devarajan P: Neutrophil gelatinase-associated lipocalin (NGAL), a new marker of kidney disease. Scand. J. Clin. Lab. Invest. Suppl. 241, 89-94 (2008).
34. Yang YH, He XJ, Chen SR, Wang L, Li EM, Xu LY: Changes of serum and urine neutrophil gelatinase-associated lipocalin in Type-2 diabetic patients with nephropathy: one year observational follow-up study. Endocrine 36(1), 45-51 (2009). ■■ Role of urinary and serum neutrophil gelatinase-associated lipocalin in predicting the progression of diabetic nephropathy.
35. Bolignano D, Lacquaniti A, Coppolino G et al.: Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press. Res. 32(2), 91-98 (2009).
36. Hall IE, Yarlagadda SG, Coca SG et al.: IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J. Am. Soc. Nephrol. 21(1), 189-197 (2010).
37. Bolignano D, Lacquaniti A, Coppolino G et al.: Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4(2), 337-344 (2009).
38. Wang Y, Lam KS, Kraegen EW et al.: Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin. Chem. 53(1), 34-41 (2007).
39. Goncalves FM, Jacob-Ferreira AL, Gomes VA et al.: Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin. Chim. Acta. 403(1-2), 173-177 (2009).
40. Merchant ML, Perkins BA, Boratyn GM et al.: Urinary peptidome may predict renal function decline in Type 1 diabetes and microalbuminuria. J. Am. Soc. Nephrol. 20(9), 2065-2074 (2009). ■■ Role of urinary peptide fragments as potential mediators of diabetic nephropathy.
41. Malyszko J, Malyszko JS, Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S, Mysliwiec M: Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients. Transplant Proc. 41(1), 158-161 (2009).
42. Kriz W: Podocyte is the major culprit accounting for the progression of chronic renal disease. Microsc. Res. Tech. 57(4), 189-195 (2002).
43. Szeto CC, Lai KB, Chow KM et al.: Messenger RNA expression of glomerular podocyte markers in the urinary sediment of acquired proteinuric diseases. Clin. Chim. Acta. 361(1-2), 182-190 (2005).
44. Sato Y, Wharram BL, Lee SK et al.: Urine podocyte mRNAs mark progression of renal disease. J. Am. Soc. Nephrol. 20(5), 1041-1052 (2009).
45. Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J: Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J. Am. Soc. Nephrol. 16(6), 1733-1741 (2005).
46. Szeto CC, Chan RW, Lai KB et al.: Messenger RNA expression of target genes in the urinary sediment of patients with chronic kidney diseases. Nephrol. Dial. Transplant. 20(1), 105-113 (2005).
47. Qi L, Cornelis MC, Kraft P et al.: Genetic variants at 2q24 are associated with susceptibility to Type 2 diabetes. Hum. Mol. Genet. 19(13), 2706-2715 (2010).
48. Shu XO, Long J, Cai Q et al.: Identification of new genetic risk variants for Type 2 diabetes. PLoS Genet. 6(9), e1001127 (2010).
49. Kottgen A, Glazer NL, Dehghan A et al.: Multiple loci associated with indices of renal function and chronic kidney disease. Nat. Genet. 41(6), 712-717 (2009).
50. Kottgen A, Pattaro C, Boger CA et al.: New loci associated with kidney function and chronic kidney disease. Nat. Genet. 42(5), 376-384 (2010).
51. Yamauchi T, Hara K, Maeda S et al.: A genome-wide association study in the Japanese population identifies susceptibility loci for Type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nat. Genet. 42(10), 864-868 (2010).
52. Zoccali C, Bode-Boger S, Mallamaci F et al.: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358(9299), 2113-2117 (2001).
53. Fliser D, Kronenberg F, Kielstein JT et al.: Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J. Am. Soc. Nephrol. 16(8), 2456-2461 (2005).
54. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339(8793), 572-575 (1992).
55. Altinova AE, Arslan M, Sepici-Dincel A, Akturk M, Altan N, Toruner FB: Uncomplicated Type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J. Clin. Endocrinol. Metab. 92(5), 1881-1885 (2007). ■ Increased asymmetrical dimethylarginine concentrations in a Type 1 diabetic patient population.
56. Salomaa V, Havulinna A, Saarela O et al.: Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One 5(4), e10100 (2010).
57. Negishi K, Noiri E, Doi K et al.: Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury. Am. J. Pathol. 174(4), 1154-1159 (2009).
58. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV: Kidney injury molecule-1 (KIM-1), a novel biomarker for human renal proximal tubule injury. Kidney Int. 62(1), 237-244 (2002).
59. Vaidya VS, Niewczas MA, Ficociello LH et al.: Regression of microalbuminuria in Type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β- dglucosaminidase. Kidney Int. 79(4), 464-470 (2010). ■ Urinary levels of kidney injury molecule-1 and N-acetyl-β-d-glucosaminidase are associated with regression of microalbuminuria in Type 1 diabetes.
60. Ziyadeh FN, Snipes ER, Watanabe M, Alvarez RJ, Goldfarb S, Haverty TP: High glucose induces cell hypertrophy and stimulates collagen gene transcription in proximal tubule. Am. J. Physiol. 259(4 Pt 2), F704-F714 (1990).
61. Polhill TS, Saad S, Poronnik P, Fulcher GR, Pollock CA: Short-term peaks in glucose promote renal fibrogenesis independently of total glucose exposure. Am. J. Physiol. Renal Physiol. 287(2), F268-F273 (2004).
62. Number of Americans with diabetes projected to double or triple by 2050. Center for Disease Control and Prevention Website. Published October 22, 2010 www.cdc.gov/media/pressrel/2010/r101022.html (Accessed 9 November 2010)